Articles related to Ambulatory Care Pharmacy (BCACP)

The FDA expanded approval of Capvaxive, a pneumococcal 21-valent conjugate vaccine, to children and adolescents aged 2 to 17 years with at least one chronic medical condition increasing pneumococcal disease risk, based on STRIDE-13 trial data showing noninferiority to PPSV23 across 12 shared serotypes and statistically significantly higher OPA GMTs for 9 serotypes unique to Capvaxive.

ASHP urged HRSA in a June 2 letter to take immediate enforcement action against Eli Lilly after the manufacturer gave an initial group of 340B-covered entities five business days to submit detailed claims-level data or lose access to discounted pricing across its full drug portfolio, including in-house hospital pharmacy dispensing and medically administered products; as of mid-June, the threatened cutoffs had not yet taken effect for many affected entities.

The American College of Physicians issued a living clinical guideline recommending semaglutide and tirzepatide as first-line pharmacologic treatments with lifestyle modifications for nonpregnant adults with obesity (BMI 30 kg/m2 or higher) or overweight (BMI 27 to 30 kg/m2) with at least one weight-related comorbidity, with phentermine-topiramate, liraglutide, and naltrexone-bupropion designated as second-, third-, and fourth-line options respectively based on GRADE evidence review.

Across the board, for all outcomes—acute pancreatitis, all-cause mortality, hospitalizations, ICU admissions—we saw significant reductions in patients on GLP-1s compared to chronic pancreatitis patients not on these drugs.” – Mahmoud Y. Madi, MD